In addition to the classical copper chelating agent tetrathiomolybdate (TM), which can be used to treat breast cancer by regulating copper homeostasis [44], the newly discovered copper chelating agent hydroxytyrosol forms a complex with copper to regulate intracellular copper levels by downregulating the phosphorylation of copper‐dependent AKT, and inhibits the aggressivity of triple‐negative breast cancer (TNBC) [45]. This evidence concerns the gene AKT1 and breast carcinoma.